AcelRx Pharmaceuticals - ACRX Stock Forecast, Price & News

AcelRx Pharmaceuticals' stock was trading at $2.26 at the beginning of 2023. Since then, ACRX stock has decreased by 70.8% and is now trading at $0.66.
View the best growth stocks for 2023 here.

AcelRx Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 666,600 shares, an increase of 7.9% from the February 13th total of 617,600 shares. Based on an average daily volume of 156,700 shares, the days-to-cover ratio is currently 4.3 days. Approximately 8.3% of the shares of the company are short sold.
View AcelRx Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our ACRX earnings forecast.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) posted its quarterly earnings results on Monday, November, 15th. The specialty pharmaceutical company reported ($1.40) EPS for the quarter, meeting analysts' consensus estimates of ($1.40). The specialty pharmaceutical company had revenue of $1.86 million for the quarter, compared to the consensus estimate of $1.20 million. During the same period in the prior year, the business posted ($2.00) earnings per share.

AcelRx Pharmaceuticals's stock reverse split on the morning of Wednesday, October 26th 2022. The 1-20 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Novavax (NVAX), Amarin (AMRN), Amicus Therapeutics (fold), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), OPKO Health (OPK), CyberArk Software (CYBR), Flexion Therapeutics (FLXN) and NVIDIA (NVDA).

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.93%), Tang Capital Management LLC (2.62%), Susquehanna International Group LLP (0.85%), Geode Capital Management LLC (0.81%), Values First Advisors Inc. (0.50%) and Texas Capital Bank Wealth Management Services Inc. (0.29%). Insiders that own company stock include Adrian Adams and Vincent J Angotti.
View institutional ownership trends.

Shares of ACRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACRX stock can currently be purchased for approximately $0.66.

AcelRx Pharmaceuticals (NASDAQ:ACRX) has a market capitalization of $4.92 million and generates $2.82 million in revenue each year. The specialty pharmaceutical company earns $-35,100,000.00 in net income (profit) each year or $6.26 on an earnings per share basis.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.acelrx.com. The specialty pharmaceutical company can be reached via phone at (650) 216-3500, via email at bkorb@troutgroup.com, or via fax at 650-216-6500.